PDCD1 and nasopharyngeal carcinoma: Toripalimab is a recombinant humanized PD-1 monoclonal antibody that has been approved by the US Food and Drug Administration (FDA) for the treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma when used with cisplatin and gemcitabine (15, 16).